sefazolin is developed by Diskapi Teaching and Research Hospital.

What development phase is sefazolin in?

sefazolin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

sefazolin

Diskapi Teaching and Research Hospital · FDA-approved active Small molecule Quality 0/100

Sefazolin, marketed by Diskapi Teaching and Research Hospital, is a drug with a key composition patent expiring in 2028. The primary strength of sefazolin lies in its current market presence, leveraging the hospital's established reputation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Generic name	sefazolin
Sponsor	Diskapi Teaching and Research Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Antibiotic Prophylaxis in Mesh Repair of Inguinal Hernias (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

sefazolin CI brief — competitive landscape report
sefazolin updates RSS · CI watch RSS
Diskapi Teaching and Research Hospital portfolio CI